Literature DB >> 14703122

Benzimidazole derivatives. 4. The recognition of the voluminous substituent attached to the basic amino group of 5-HT4 receptor antagonists.

Maria L López-Rodríguez1, Bellinda Benhamú, Marta Murcia, Elsa Alvaro, Mercedes Campillo, Leonardo Pardo.   

Abstract

We report a structure-affinity analysis of an important element in the pharmacophore model for the recognition of 5-HT4 receptor antagonists: the voluminous substituent attached to the basic nitrogen of the ligand. We have designed, synthesized and pharmacologically evaluated a series of benzimidazole derivatives 1 containing a common molecular skeleton formed by N-[(4-piperidyl)methyl]-6-chlorobenzimidazole-4-carboxamide and four different substituents (R = butyl, 2-[(methylsulfonyl)amino]ethyl, 5-[(phenylacetyl)amino]pentyl, and 5-[(benzylsulfonyl)amino]pentyl). These compounds possess binding affinities in the nM range (Ki = 0.11-1.50 nM). Moreover, a ligand that contains a hydrogen atom attached to the basic nitrogen (R = H; Ki = 150 nM) is used as a control for structure-affinity relationships.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14703122     DOI: 10.1023/b:jcam.0000004601.34056.c1

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  31 in total

1.  A single mutation in the 5-HT4 receptor (5-HT4-R D100(3.32)A) generates a Gs-coupled receptor activated exclusively by synthetic ligands (RASSL).

Authors:  Sylvie Claeysen; Lara Joubert; Michèle Sebben; Joël Bockaert; Aline Dumuis
Journal:  J Biol Chem       Date:  2002-11-18       Impact factor: 5.157

2.  The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer.

Authors:  Wen Guo; Lei Shi; Jonathan A Javitch
Journal:  J Biol Chem       Date:  2002-12-19       Impact factor: 5.157

3.  Benzimidazole derivatives. Part 1: Synthesis and structure-activity relationships of new benzimidazole-4-carboxamides and carboxylates as potent and selective 5-HT4 receptor antagonists.

Authors:  M L López-Rodríguez; B Benhamú; A Viso; M J Morcillo; M Murcia; L Orensanz; M J Alfaro; M I Martín
Journal:  Bioorg Med Chem       Date:  1999-11       Impact factor: 3.641

4.  Raster3D: photorealistic molecular graphics.

Authors:  E A Merritt; D J Bacon
Journal:  Methods Enzymol       Date:  1997       Impact factor: 1.600

5.  Serine and threonine residues bend alpha-helices in the chi(1) = g(-) conformation.

Authors:  J A Ballesteros; X Deupi; M Olivella; E E Haaksma; L Pardo
Journal:  Biophys J       Date:  2000-11       Impact factor: 4.033

6.  Benzimidazole derivatives. 3. 3D-QSAR/CoMFA model and computational simulation for the recognition of 5-HT(4) receptor antagonists.

Authors:  María L López-Rodríguez; Marta Murcia; Bellinda Benhamú; Alma Viso; Mercedes Campillo; Leonardo Pardo
Journal:  J Med Chem       Date:  2002-10-24       Impact factor: 7.446

7.  Synthesis and structure-activity relationships of a new model of arylpiperazines. Study of the 5-HT(1a)/alpha(1)-adrenergic receptor affinity by classical hansch analysis, artificial neural networks, and computational simulation of ligand recognition.

Authors:  M L López-Rodríguez; M J Morcillo; E Fernández; M L Rosado; L Pardo; K Schaper
Journal:  J Med Chem       Date:  2001-01-18       Impact factor: 7.446

8.  A 5-HT4 receptor transmembrane network implicated in the activity of inverse agonists but not agonists.

Authors:  Lara Joubert; Sylvie Claeysen; Michèle Sebben; Anne-Sophie Bessis; Robin D Clark; Renee S Martin; Joël Bockaert; Aline Dumuis
Journal:  J Biol Chem       Date:  2002-04-25       Impact factor: 5.157

9.  Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F.

Authors:  S P Sheikh; T A Zvyaga; O Lichtarge; T P Sakmar; H R Bourne
Journal:  Nature       Date:  1996-09-26       Impact factor: 49.962

10.  Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor.

Authors:  U Gether; S Lin; P Ghanouni; J A Ballesteros; H Weinstein; B K Kobilka
Journal:  EMBO J       Date:  1997-11-17       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.